Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

Cited by (1,000)

Items 301–400 of 1,000

1. A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells
   Michele Bombardieri, Ngar‐Woon Kam, Fabia Brentano, Ken Lee Choi, Andrew D. Filer, Diego Kyburz, Iain B. McInnes, Steffen Gay, Christopher Dominic Buckley, Costantino Pitzalis · 2011 · Annals of the Rheumatic Diseases
2. The role of B cells in lupus pathogenesis
   Emil Pablo Nashi, Yinghua Wang, Betty Diamond · 2009 · The International Journal of Biochemistry & Cell Biology
3. A Randomized, Doubleblind, Placebo-Controlled, Study of Single-Dose Rituximab as Induction in Renal Transplantation
   Gunnar Tydén, Helena Genberg, Jan G. Tollemar, Henrik Ekberg, Nils H. Persson, Gunnar Tufveson, Jonas Wadström, Markus Gäbel, Lars Mjörnstedt · 2009 · Transplantation
4. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis
   Carine Salliot, Axel Finckh, Wanruchada Katchamart, Yan Lu, Ye Sun, Claire Bombardier, E. Keystone · 2010 · Annals of the Rheumatic Diseases
5. Treatment of rheumatoid arthritis
   Paul Emery · 2006 · BMJ
6. Osteoimmunology The i Nexus i between bone and immune system
   Rupesh Kumar Srivastava · 2017 · Frontiers in bioscience
7. Osteoimmunology
   Kazuo Okamoto, Hiroshi Takayanagi · 2018 · Cold Spring Harbor Perspectives in Medicine
8. Treating very early rheumatoid arthritis
   Karim Raza, Caitriona E. Buckley, Mike Salmon, Christopher Dominic Buckley · 2006 · Best Practice & Research Clinical Rheumatology
9. Immune complexes regulate bone metabolism through FcRγ signalling
   Takako Negishi‐Koga, Hans-Jürgen Gober, Eriko Sumiya, Noriko Komatsu, Kazuo Okamoto, Shinichiro Sawa, Ayako Suematsu, Tomomi Suda, Kojiro Sato, Toshiyuki Takai et al. · 2015 · Nature Communications
10. Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response
    Diana G. Adlowitz, Jennifer Barnard, Jamie N. Biear, Christopher Cistrone, Teresa Owen, Wensheng Wang, Arumugam Palanichamy, Ezinma Ezealah, Debbie Campbell, Chungwen Wei et al. · 2015 · PLoS ONE
11. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy
    Gregory J. Keir, Toby M. Maher, David M. Hansell, Christopher Paul Denton, Voon Hong Ong, Suveer Singh, Athol Umfrey Wells, Elisabetta Augusta Renzoni · 2012 · European Respiratory Journal
12. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis
    M S Kavuru, Achut G. Malur, Irene Marshall, Barbara P. Barna, Moulay A. Meziane, Isham Huizar, Heidi Dalrymple, Reema R. Karnekar, Mary Jane Thomassen · 2011 · European Respiratory Journal
13. Recommendations for the use of rituximab (anti‐CD20 antibody) in the treatment of autoimmune bullous skin diseases§
    Michael Hertl, Detlef Zillikens, Luca Borradori, Leena Bruckner‐Tuderman, Harald Burckhard, Rüdiger Eming, Andreas Engert, Matthias Goebeler, Silke C Hofmann, Nicolas Hunzelmann et al. · 2008 · JDDG Journal der Deutschen Dermatologischen Gesellschaft
14. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design
    Venkat R Reddy, David R.W. Jayne, David R. Close, David Alan Isenberg · 2013 · Arthritis Research & Therapy
15. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
    Paul Emery, Anthony I. Sebba, Tom W. J. Huizinga · 2013 · Annals of the Rheumatic Diseases
16. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response
    Magda Nakou, Georgios Katsikas, Prodromos I. Sidiropoulos, George K Bertsias, Eva D. Papadimitraki, Amalia Raptopoulou, Helen Koutala, Helen Α. Papadaki, Herakles D. Kritikos, Dimitrios T. Boumpas · 2009 · Arthritis Research & Therapy
17. Anti-CD20 monoclonal antibodies: reviewing a revolution
    Joshua M. L. Casan, Jonathan Wong, Melissa Northcott, Stephen Opat · 2018 · Human Vaccines & Immunotherapeutics
18. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation
    Julio Ramírez, Juan de Dios Cañete · 2018 · Expert Opinion on Drug Safety
19. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab
    Henrik E. Mei, Daniela Frölich, Claudia Giesecke‐Thiel, Christoph Loddenkemper, Karin Reiter, Stefanie Schmidt, Eugen Feist, Capucine Daridon, Hans‐Peter Tony, Andreas Radbruch et al. · 2010 · Blood
20. Update on the genetic architecture of rheumatoid arthritis
    Kwang-Woo Kim, So‐Young Bang, Hye‐Soon Lee, Sang‐Cheol Bae · 2016 · Nature Reviews Rheumatology
21. Effector and regulatory B cells in immune-mediated kidney disease
    Kristīne Oļeiņika, Claudia Mauri, Alan David Salama · 2018 · Nature Reviews Nephrology
22. Follicular Dendritic Cells Are Related to Bone Marrow Stromal Cell Progenitors and to Myofibroblasts
    Raquel Muñoz‐Fernández, Francisco Javier Blanco, Cecilia A. Frecha, Francisco Martı́n, María Kimatrai, Ana Clara Abadía‐Molina, José Marcos García-Pacheco, Enrique G. Olivares · 2006 · The Journal of Immunology
23. Rheumatoid Arthritis: The Role of Reactive Oxygen Species in Disease Development and Therapeutic Strategies
    Kyra A. Gelderman, Malin Hopkins Hultqvist, Lina M. Olsson, Kristin Bauer, Angela Pizzolla, Peter Olofsson, Rikard Holmdahl · 2007 · Antioxidants and Redox Signaling
24. Structural Basis for Recognition of CD20 by Therapeutic Antibody Rituximab
    Jiamu Du, Hao Wang, Chen Zhong, Baozhen Peng, Meilan Zhang, Bohua Li, Sheng Huo, Yajun Guo, Jianping Ding · 2007 · Journal of Biological Chemistry
25. Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis
    Kutty Selva Nandakumar, R. Holmdahl · 2007 · Arthritis Research & Therapy
26. Rituximab in refractory autoimmune bullous diseases
    Enno Schmidt, Nicolas Hunzelmann, Detlef Zillikens, E.-B. Bröcker, M. Goebeler · 2006 · Clinical and Experimental Dermatology
27. Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll‐like receptors in immunity
    Lampropoulou, Vicky, Calderon‐Gomez, Elisabeth, Roch, Toralf, Neves, Patricia, Shen, Ping, Stervbo, Ulrik, Boudinot, Pierre, Anderton, Stephen M., Fillatreau, Simon · 2010 · Immunological Reviews
28. Long‐term follow‐up of febrile infection–related epilepsy syndrome
    Katherine B. Howell, Kamornwan Katanyuwong, Mark Thomas Mackay, Catherine Bailey, Ingrid Eileen Scheffer, Jeremy L. Freeman, Samuel Frank Berkovic, Anthony Simon Harvey · 2011 · Epilepsia
29. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
    Josée Golay, Elena Cittera, Nicola Di Gaetano, Massimiliano Manganini, Michela Mosca, Manuela Nebuloni, Nico van Rooijen, Luca Vago, Martino Introna · 2006 · PubMed
30. Expression of CD80/86 on B Cells Is Essential for Autoreactive T Cell Activation and the Development of Arthritis
    Shannon K. O’Neill, Yanxia Cao, Keith M. Hamel, Paul D. Doodes, Gábor Hutás, Alison Finnegan · 2007 · The Journal of Immunology
31. Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity
    Marieke E. Doorenspleet, Paul L. Klarenbeek, Maria J. H. de Hair, Barbera D. C. van Schaik, R. E. Esveldt, Antoine H. C. van Kampen, Daniëlle M. Gerlag, Annelie H. Musters, Frank Baas, Paul Peter Tak et al. · 2013 · Annals of the Rheumatic Diseases
32. The therapeutic potential of anti-CD20
    Robert A. Eisenberg, Richard John Looney · 2005 · Clinical Immunology
33. Current Immunotherapy in Rheumatoid Arthritis
    Florian M. P. Meier, M. Frerix, W. Hermann, Ulf Müller‐Ladner · 2013 · Immunotherapy
34. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial
    Peter Charles Taylor, Emilia Quattrocchi, Stephen A. Mallett, Regina Kurrasch, Jørgen Holm Petersen, David Joey Chang · 2011 · Annals of the Rheumatic Diseases
35. Drug Insight: rituximab in renal disease and transplantation
    Alan David Salama, Charles Dickson Pusey · 2006 · Nature Reviews Nephrology
36. Mesenchymal stem cells and autoimmune diseases
    Francesco Dazzi, Mauro Krampera · 2011 · Best Practice & Research Clinical Haematology
37. Hepatitis B reactivation in HBsAg‐negative/HBcAb‐positive patients receiving rituximab for lymphoma: a meta‐analysis
    Lee Mozessohn, Kelvin Chan, Jordan J. Feld, Lisa K. Hicks · 2015 · Journal of Viral Hepatitis
38. Rituximab may form a complex with iGmκ mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus–induced vasculitis
    D. Sène, Pascale Ghillani‐Dalbin, Zahir Amoura, L. Musset, P. Cacoub · 2009 · Arthritis & Rheumatism
39. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus
    Yoshiya Tanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi, Norihiro Nishimoto, Nobuyuki Miyasaka, Takayuki Sumida, Yoshihito Shima, Kazuki Takada, Isao Matsumoto, Kazuyoshi Saito et al. · 2007 · Modern Rheumatology
40. Pharmacotherapy Options in Rheumatoid Arthritis
    Pradeep Kumar, Snehashish Banik · 2013 · Clinical Medicine Insights Arthritis and Musculoskeletal Disorders
41. Rituximab for rheumatoid arthritis
    Maria Angeles Lopez-Olivo, Matxalen Amezaga, Lynda McGahan, Eduardo N. Pollono, Maria Eugenia Suarez-Almazor · 2015 · Cochrane Database of Systematic Reviews
42. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease
    Stefanie Sarantopoulos, Kristen E. Stevenson, Haesook T. Kim, Whitney Washel, Nazmim S. Bhuiya, Corey S. Cutler, Edwin Pascal Alyea, Vincent T. Ho, Robert J. Soiffer, Joseph H. Antin et al. · 2010 · Blood
43. Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial
    Yves Allenbach, Marguerite Guiguet, Aude Rigolet, Isabelle Marié, Eric HACHULLA, Laurent Drouot, Fabienne Jouen, Serge Jacquot, K. Mariampillai, L. Musset et al. · 2015 · PLoS ONE
44. IgG and Fcγ Receptors in Intestinal Immunity and Inflammation
    Tomas Castro‐Dopico, Menna Ruth Clatworthy · 2019 · Frontiers in Immunology
45. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009
    D E Furst, Edward Clark Keystone, R Fleischmann, Philip J. Mease, Breedveld Fc, Josef S Smolen, J R Kalden, Jürgen Braun, B Bresnihan, Gerd Rüdiger Burmester et al. · 2009 · Annals of the Rheumatic Diseases
46. Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial
    Philip J. Mease, Stanley B. Cohen, NORMAN B. GAYLIS, Andrew Chubick, Alan T. Kaell, Maria Greenwald, Sunil Kumar Agarwal, MING YIN, Ariella Kelman · 2010 · The Journal of Rheumatology
47. Combination therapy in multiple sclerosis.
    Devon S. Conway, Jeffrey A. Cohen · 2010 · Lancet Neurology
48. Rheumatoid arthritis in review: Clinical, anatomical, cellular and molecular points of view
    Κassem Sharif, Alaa Mohammad Sharif, Fareed Jumah, Rod J. Oskouian, Richard Shane Tubbs · 2017 · Clinical Anatomy
49. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event
    Joseph R. Berger, Vineeta Malik, Stuart Lacey, Paul G. Brunetta, Patricia B. Lehane · 2018 · Journal of NeuroVirology
50. Treatment of rheumatoid arthritis: Unraveling the conundrum
    Evangelia Zampeli, Panayiotis G. Vlachoyiannopoulos, Athanasios G. Tzioufas · 2015 · Journal of Autoimmunity
51. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
    James L. Rubenstein, Jing Li, Lingjing Chen, Ranjana H. Advani, Jan Drappatz, Elizabeth Robins Gerstner, Tracy T. Batchelor, Hendrikus G. J. Krouwer, James Q. Hwang, Glenna M. Auerback et al. · 2012 · Blood
52. Immunopathogenesis of Thyroid Eye Disease: Emerging Paradigms
    Vibhavari Milind Naik, Milind N. Naik, Robert A. Goldberg, Terry J. Smith, Raymond S. Douglas · 2010 · Survey of Ophthalmology
53. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis
    Ekaterina I. Alexeeva, Saniya I Valieva, Tatyana M. Bzarova, Elena L. Semikina, Kseniya B. Isaeva, A.O. Lisitsyn, Rina V. Denisova, Е. G. Chistyakova · 2011 · Clinical Rheumatology
54. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
    Daniel E. Fürst, Edward Clark Keystone, Joseph M. Braun, Breedveld Fc, Gerd Rüdiger Burmester, Fabrizio De Benedetti, Thomas Dörner, Paul Emery, Roy Fleischmann, A. Gibofsky et al. · 2012 · Annals of the Rheumatic Diseases
55. Rheumatoid Arthritis: A Role for Immunosenescence?
    Tamsin M. Lindström, William H. Robinson · 2010 · Journal of the American Geriatrics Society
56. Pharmacokinetics of rituximab and its clinical use: Thought for the best use?
    Guillaume Cartron, Hélène Blasco, Gilles Paintaud, Hervé Watier, Chantal Barin‐Le Guellec · 2007 · Critical Reviews in Oncology/Hematology
57. Novel therapies for coeliac disease
    Ludvig Magne Sollid, Chaitan Khosla · 2011 · Journal of Internal Medicine
58. Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective
    F. De Keyser · 2011 · Current Rheumatology Reviews
59. IL-33 Exacerbates Autoantibody-Induced Arthritis
    Damo Xu, Hui‐Rong Jiang, Yubin Li, Peter Natesan Pushparaj, Mariola Kurowska‐Stolarska, Bernard P. L. Leung, Rong Mu, Hwee Kee Tay, Andrew N. J. McKenzie, Iain B. McInnes et al. · 2010 · The Journal of Immunology
60. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis
    Maria Rehnberg, Sylvie Amu, Andrej Tarkowski, Maria I Bokarewa, Mikael Brisslert · 2009 · Arthritis Research & Therapy
61. Destructive Roles of Fibroblast-like Synoviocytes in Chronic Inflammation and Joint Damage in Rheumatoid Arthritis
    Maryam Masoumi, Hamidreza Bashiri, Hossein Khorramdelazad, Khadijeh Barzaman, Nader Hashemi, Hale Abdoli Sereshki, Amirhossein Sahebkar, Jafar Karami · 2020 · Inflammation
62. Rituximab in Severe Pemphigus
    Enno Schmidt, Matthias Goebeler, Detlef Zillikens · 2009 · Annals of the New York Academy of Sciences
63. Patients with Rheumatoid Arthritis Undergoing Surgery: How Should We Deal with Antirheumatic Treatment?
    Herwig Pieringer, Ulrike Stuby, Georg Biesenbach · 2007 · Seminars in Arthritis and Rheumatism
64. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
    Henrik E. Mei, Stefanie Schmidt, Thomas Dörner · 2012 · Arthritis Research & Therapy
65. Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases
    Christine Riedhammer, Robert Weissert · 2015 · Frontiers in Immunology
66. Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy
    Y. A. de Man, Liesbeth E. Bakker‐Jonges, C M Dufour-van den Goorbergh, S P R Tillemans, Herbert Hooijkaas, J. M. W. Hazes, Radboud J. E. M. Dolhain · 2009 · Annals of the Rheumatic Diseases
67. Interleukin-7 induced immunopathology in arthritis
    Sarita A. Y. Hartgring, J. W. J. Bijlsma, Floris P. J. G. Lafeber, Joël A. G. van Roon · 2006 · Annals of the Rheumatic Diseases
68. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis
    A Bhatia, Peter Josef Ell, Jonathan Edwards · 2005 · Annals of the Rheumatic Diseases
69. Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers
    Thomas Dörner, Nils Kinnman, Paul Peter Tak · 2010 · Pharmacology & Therapeutics
70. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis
    Rogier M. Thurlings, Onno YK Teng, Koen Vos, Daniëlle M. Gerlag, Lucien A. Aarden, Steven O. Stapel, Jacob M. van Laar, Paul Peter Tak, Gertjan Wolbink · 2009 · Annals of the Rheumatic Diseases
71. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics
    Ying‐Ming Chiu, Der‐Yuan Chen · 2019 · Expert Review of Clinical Immunology
72. Treatment-Resistant Severe, Active Graves' Ophthalmopathy Successfully Treated with B Lymphocyte Depletion
    Daniel El Fassi, Claus Henrik Nielsen, Hans Carl Hasselbalch, László Dávid Hegedűs · 2006 · Thyroid
73. Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis
    Yasuto Araki, Toshihide Mimura · 2017 · International Journal of Molecular Sciences
74. Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis
    Hendy Kristyanto, Nienke J. Blomberg, Linda M. Slot, Ellen I. H. van der Voort, Priscilla F. Kerkman, Aleida M. Bakker, Leonie E. Burgers, Robin M. ten Brinck, Annette H M van der Helm–van Mil, Hergen Spits et al. · 2020 · Science Translational Medicine
75. Genetic deficiency of Syk protects mice from autoantibody‐induced arthritis
    Zoltán Jakus, Edina Simon, Bálint Balázs, Attila Mócsai · 2010 · Arthritis & Rheumatism
76. Update on the treatment of lupus nephritis
    Meryl A. Waldman, Gerald B. Appel · 2006 · Kidney International
77. Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2)
    Julia E. Graves, Kara S. Nunley, Michael P. Heffernan · 2006 · Journal of the American Academy of Dermatology
78. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008
    Daniel E. Fürst, Edward Clark Keystone, B. Kirkham, R Fleischmann, Philip J. Mease, Breedveld Fc, Josef S Smolen, J R Kalden, Gerd Rüdiger Burmester, J. Braun et al. · 2008 · Annals of the Rheumatic Diseases
79. PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis
    H. Benjamin Larman, Uri Laserson, Luís Querol, Katrijn Verhaeghen, Nicole L. Solimini, George Jing Xu, Paul L. Klarenbeek, George McDonald Church, David A. Hafler, Robert M. Plenge et al. · 2013 · Journal of Autoimmunity
80. Cancer targeted therapeutics: From molecules to drug delivery vehicles
    Daxing Liu, Debra T. Auguste · 2015 · Journal of Controlled Release
81. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis
    Mary‐Jane Guerry, Paul A. Brogan, Ian N Bruce, David P. D’Cruz, Lorraine Harper, Raashid Ahmed Luqmani, Charles Dickson Pusey, Alan David Salama, David G. I. Scott, Caroline O. S. Savage et al. · 2011 · Lara D. Veeken
82. Pathogenic Complement Activation in Collagen Antibody- Induced Arthritis in Mice Requires Amplification by the Alternative Pathway
    Nirmal K. Banda, Kazue Takahashi, Allyson Wood, Vernon Michael Holers, William P. Arend · 2007 · The Journal of Immunology
83. Collagen-Induced Arthritis as an Animal Model for Rheumatoid Arthritis: Focus on Interferon-γ
    Evelien Schurgers, Alfons Billiau, Patrick Matthys · 2011 · Journal of Interferon & Cytokine Research
84. Impact of Aetiological Treatment on Conventional and Multiplex Serology in Chronic Chagas Disease
    Rodolfo J. Viotti, Carlos Vigliano, María Gabriela Álvarez, Bruno Lococo, Marcos A. Petti, Graciela L. Bertocchi, Alejandro Armenti, Ana Maria De Rissio, Gretchen M. Cooley, Rick L. Tarleton et al. · 2011 · PLoS neglected tropical diseases
85. B Cells Drive Early T Cell Autoimmunity In Vivo prior to Dendritic Cell-Mediated Autoantigen Presentation
    Jun Yan, Bohdan P. Harvey, Renelle J. Gee, Mark Jay Shlomchik, Mark J. Mamula · 2006 · The Journal of Immunology
86. Continuous inhibitory signaling by both SHP-1 and SHIP-1 pathways is required to maintain unresponsiveness of anergic B cells
    Andrew Getahun, Nicole A. Beavers, Sandy R. Larson, Mark Jay Shlomchik, John C. Cambier · 2016 · The Journal of Experimental Medicine
87. Inhibitory Role of CD19 in the Progression of Experimental Autoimmune Encephalomyelitis by Regulating Cytokine Response
    Takashi Matsushita, Manabu Fujimoto, Minoru Hasegawa, Kazuhiro Komura, Kazuhiko Takehara, Thomas F. Tedder, Shinichi Sato · 2006 · American Journal Of Pathology
88. Methotrexate in rheumatoid arthritis
    Edwin S. L. Chan, Patricia Fernández, Bruce Neil Cronstein · 2006 · Expert Review of Clinical Immunology
89. Rituximab in the treatment of antisynthetase syndrome
    Laure Brulhart, J-M Waldburger, C Gabay · 2006 · Annals of the Rheumatic Diseases
90. Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune‐mediated disorders
    James N. George, Robert D. Woodson, Joseph E. Kiss, Kiarash Kojouri, Sara K. Vesely · 2006 · Journal of Clinical Apheresis
91. Rituximab and Immune Deficiency: Case Series and Review of the Literature
    Blanka M. Kaplan, Yelena Kopyltsova, Amrita Khokhar, Fung Lam, Vincent Robert Bonagura · 2014 · The Journal of Allergy and Clinical Immunology In Practice
92. Ofatumumab, a human anti‐CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease‐modifying antirheumatic drugs: Results of a randomized, double‐blind, placebo‐controlled, phase I/II study
    Mikkel Østergaard, Bo Baslund, William F. C. Rigby, Bernadette Rojkovich, Christian Jørgensen, Peter T Dawes, Charlotte Wiell, Daniel J. Wallace, Soren Can Tamer, Helle Kastberg et al. · 2010 · Arthritis & Rheumatism
93. Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis
    Alexei A. von Delwig, James Locke, John H. Robinson, Wan‐Fai Ng · 2009 · Arthritis & Rheumatism
94. The Emerging Role of Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/cfs)
    Gerwyn Morris, Michael Berk, Piotr Gałecki, Michael H. J. Maes · 2013 · Molecular Neurobiology
95. Increased Concentrations of Antibody-Bound Circulatory Cell-Free DNA in Rheumatoid Arthritis
    Xiaoyan Zhong, Ines von Mühlenen, Ying Li, Anjeung Kang, Anurag Kumar Gupta, Alan Tyndall, Wolfgang Holzgreve, Sinuhe Hahn, Paul Hasler · 2007 · Clinical Chemistry
96. Rituximab Therapy for Primary Sjögren's Syndrome: An Open‐Label Clinical Trial and Mechanistic Analysis
    E. William St. Clair, Marc C. Levesque, Eline T. Luning Prak, Frederick B. Vivino, Chacko J. Alappatt, Meagan E. Spychala, Josiah F. Wedgwood, James McNamara, Kathy L. Moser Sivils, Lytia Fisher et al. · 2013 · Arthritis & Rheumatism
97. Anti-CD20–mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives
    Étienne Crickx, Jean–Claude Weill, Claude–Agnès Reynaud, Matthieu Mahévas · 2020 · Kidney International
98. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action
    Jagadeesh Bayry, Sébastien Lacroix‐Desmazes, Michel Daniel Kazatchkine, Srini V. Kaveri · 2007 · Nature Clinical Practice Rheumatology
99. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor
    Federico Perosa, Elvira Favoino, Maria Antonietta Caragnano, Franco Dammacco · 2005 · Blood
100. B cells in rheumatoid arthritis: from hypothesis to the clinic
     Edward Clark Keystone · 2005 · Lara D. Veeken